TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25970009

Group type: EXPERIMENTAL
Intervention: Reward-based programs (approximately $800 for smoking cessation)
Number of subjects: 2538

Group type: EXPERIMENTAL
Intervention: Deposit-based programs ($150 refundable deposit plus $650 in reward payments)
Number of subjects: 2538

Group type: COMPARATOR
Intervention: Usual care (informational resources and free smoking-cessation aids)
Number of subjects: 2538

Group type: EXPERIMENTAL
Intervention: Group-oriented programs
Number of subjects: 2538

Group type: EXPERIMENTAL
Intervention: Individual-oriented programs
Number of subjects: 2538

Group type: EXPERIMENTAL
Intervention: Reward-based programs
Number of subjects: 2538

Group type: EXPERIMENTAL
Intervention: Deposit-based programs
Number of subjects: 2538
Study: 23605170

Group type: EXPERIMENTAL
Intervention: Metformin (1,500 mg) and folic acid (1 mg) per day for 2 months
Number of subjects: 359

Group type: COMPARATOR
Intervention: Folic acid (1 mg) per day for 2 months (Control)
Number of subjects: 359
Study: 22084374

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus docetaxel (GD)
Number of subjects: 337

Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 337
Study: 19620848

Group type: EXPERIMENTAL
Intervention: IPX054 (50/200 mg) twice daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: CD/LD (25/100 mg) 4 times daily
Number of subjects: 12
Study: 16836171

Group type: EXPERIMENTAL
Intervention: Acellular dermal matrix (ADM) allograft
Number of subjects: 1

Group type: COMPARATOR
Intervention: Palatal autograft
Number of subjects: 1
Study: 12612511

Group type: EXPERIMENTAL
Intervention: 5 mg midazolam plus 50 mg meperidine (Group B)
Number of subjects: 253

Group type: COMPARATOR
Intervention: 5 mg midazolam and placebo (Group A)
Number of subjects: 253
Study: 10852763

Group type: EXPERIMENTAL
Intervention: Oxitropium bromide 400 microg
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 8811136

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (Voltaren), 50 mg two or three times a day
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 1329231

Group type: EXPERIMENTAL
Intervention: Teniposide administration (schedule not specified)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Teniposide with cisplatin (schedule not specified)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Teniposide without cisplatin (schedule not specified)
Number of subjects: 80
Study: 6724125

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) 200 mg tablets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ) 400 mg tablets
Number of subjects: 0
Study: 29618121

Group type: EXPERIMENTAL
Intervention: Strategic bDMARDs treatment (ustekinumab, secukinumab, TNF inhibitors based on T cell phenotype)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Standard bDMARDs treatment
Number of subjects: 64
Study: 29521922

Group type: EXPERIMENTAL
Intervention: Foot exercises (daily for 12 weeks)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Standard wound care with foot exercises
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (standard wound care only)
Number of subjects: 60
Study: 25695485

Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 1059

Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 1059
Study: 23726668

Group type: EXPERIMENTAL
Intervention: Citalopram treatment for 12 weeks
Number of subjects: 1116
Study: 21346736

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 0
Study: 18766387

Group type: EXPERIMENTAL
Intervention: beta‐TCP (Cerasorb) in combination with PRP
Number of subjects: 22

Group type: COMPARATOR
Intervention: beta‐TCP (Cerasorb) alone
Number of subjects: 22
Study: 17207645

Group type: EXPERIMENTAL
Intervention: Degenerative meniscus tear (diagnosed by MRI)
Number of subjects: 41

Group type: COMPARATOR
Intervention: No degenerative meniscus tear
Number of subjects: 41
Study: 16739362

Group type: EXPERIMENTAL
Intervention: Iberogast (3 x 20 drops daily for 4 weeks)
Number of subjects: 592

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 592

Group type: COMPARATOR
Intervention: Cisapride (positive control)
Number of subjects: 592
Study: 11321874

Group type: EXPERIMENTAL
Intervention: G-CSF or GM-CSF
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 8199081

Group type: EXPERIMENTAL
Intervention: Interceed (absorbable adhesion barrier)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Conventional microsurgery with hydrocortisone
Number of subjects: 28
Study: 3444905

Group type: EXPERIMENTAL
Intervention: lonidamine (150 mg t.i.d.) + radiotherapy (RT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: placebo (PLAC) + radiotherapy (RT)
Number of subjects: 50
Study: 29409951

Group type: EXPERIMENTAL
Intervention: Benralizumab every 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28494910

Group type: EXPERIMENTAL
Intervention: Maternal presence during anesthesia induction
Number of subjects: 48

Group type: COMPARATOR
Intervention: Separation from mothers during anesthesia induction
Number of subjects: 48
Study: 26561632

Group type: EXPERIMENTAL
Intervention: Vaccenic acid (VA)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Industrial trans fatty acids (iTFA)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: c9,t11-conjugated linoleic acid (c9,t11-CLA)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control diet (0.1% mixed isomers of TFA)
Number of subjects: 106
Study: 24009137

Group type: EXPERIMENTAL
Intervention: L-thyroxine replacement therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (healthy women)
Number of subjects: 20
Study: 21262507

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 178

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study: 18978623

Group type: EXPERIMENTAL
Intervention: Static stretching (1 x 20, 2 x 20, 3 x 20)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Static stretching (1 x 20, 1 x 40) and PNF stretching
Number of subjects: 34

Group type: COMPARATOR
Intervention: Low volume of static stretching
Number of subjects: 34
Study: 16580290

Group type: COMPARATOR
Intervention: Isosorbide mononitrate (40 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (2 mg)
Number of subjects: 0
Study: 12680890

Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg x 4 for 3 days
Number of subjects: 36

Group type: COMPARATOR
Intervention: Paracetamol 1000 mg x 4 for 3 days
Number of subjects: 36
Study: 10974183

Group type: EXPERIMENTAL
Intervention: Exercise training program (cycling, walking, strength training)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual medical care
Number of subjects: 100
Study: 9096920

Group type: EXPERIMENTAL
Intervention: Adenosine RNVG
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Dobutamine RNVG
Number of subjects: 41

Group type: COMPARATOR
Intervention: Exercise RNVG
Number of subjects: 41
Study: 8342751

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Thiopentone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 40
Study: 3555364

Group type: EXPERIMENTAL
Intervention: Parietal cell vagotomy (PCV)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Selective vagotomy and antrectomy (SV-A)
Number of subjects: 200
Study: 31057139

Group type: EXPERIMENTAL
Intervention: Negatively-valenced Affective Six Elements Test (A-SET)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Positively-valenced Affective Six Elements Test (A-SET)
Number of subjects: 60
Study: 30158057

Group type: EXPERIMENTAL
Intervention: Increased dose of loop diuretics
Number of subjects: 2004

Group type: COMPARATOR
Intervention: Continuous use of loop diuretics
Number of subjects: 2004

Group type: EXPERIMENTAL
Intervention: Initiation or discontinuation of diuretics
Number of subjects: 2004
Study: 27647847

Group type: EXPERIMENTAL
Intervention: Renal artery stenting plus optimal medical therapy
Number of subjects: 947

Group type: COMPARATOR
Intervention: Optimal medical therapy alone
Number of subjects: 947
Study: 24721114

Group type: EXPERIMENTAL
Intervention: Wiki (experimental intervention)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Discussion group (control intervention)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both methods (Wiki and Discussion group)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Recommendations produced by participants
Number of subjects: 20
Study: 23706520

Group type: EXPERIMENTAL
Intervention: Spironolactone 25 mg daily for 20 weeks
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 20530299

Group type: EXPERIMENTAL
Intervention: Strict blood pressure control (<140 mm Hg)
Number of subjects: 3260

Group type: COMPARATOR
Intervention: Moderate blood pressure control (>=140 mm Hg to <150 mm Hg)
Number of subjects: 3260
Study: 18155609

Group type: EXPERIMENTAL
Intervention: Curcuminoids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NRS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VAS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MOMI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Erythema plus ulceration
Number of subjects: 0
Study: 16157752

Group type: EXPERIMENTAL
Intervention: Lactate infusion
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Glucose infusion
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Intralipid infusion
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cycle exercise
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Second wind phenomenon
Number of subjects: 12
Study: 12515740

Group type: EXPERIMENTAL
Intervention: TAXUS stent (n=31)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control stent (n=30)
Number of subjects: 61
Study: 10664641

Group type: EXPERIMENTAL
Intervention: Remote video technology in home health care setting
Number of subjects: 212

Group type: COMPARATOR
Intervention: Routine home health care (control)
Number of subjects: 212
Study: 8833507

Group type: EXPERIMENTAL
Intervention: Clinical examination of tooth surfaces
Number of subjects: 4294

Group type: EXPERIMENTAL
Intervention: Molar occlusal surfaces
Number of subjects: 4294

Group type: EXPERIMENTAL
Intervention: Pit and fissure caries
Number of subjects: 4294

Group type: EXPERIMENTAL
Intervention: Interproximal surfaces
Number of subjects: 4294

Group type: EXPERIMENTAL
Intervention: Smooth surfaces
Number of subjects: 4294

Group type: EXPERIMENTAL
Intervention: 3-year increments of caries
Number of subjects: 4294
Study: 8305642

Group type: EXPERIMENTAL
Intervention: GFR measurements using renal clearance of [125I]iothalamate after an sc injection without epinephrine.
Number of subjects: 2250
Study: 2863920

Group type: EXPERIMENTAL
Intervention: Alprazolam (AZ) 0.25 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Diazepam (DZ) 5 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Alprazolam (AZ) 0.75 mg
Number of subjects: 24
Study: 31888551

Group type: EXPERIMENTAL
Intervention: Nimotuzumab combined with cisplatin plus 5-fluorouracil (NPF group)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Docetaxel combined with cisplatin plus 5-fluorouracil (DPF group)
Number of subjects: 118
Study: 29889923

Group type: EXPERIMENTAL
Intervention: Crestal sinus lift elevation using the CAS kit with grafting (anorganic bovine bone)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Crestal sinus lift elevation using the CAS kit without grafting
Number of subjects: 35
Study: 27513584

Group type: EXPERIMENTAL
Intervention: EX/RP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: risperidone
Number of subjects: 0
Study: 24802974

Group type: EXPERIMENTAL
Intervention: 20 mg oral Δ(9) -tetrahydrocannabinol (THC)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 23036785

Group type: EXPERIMENTAL
Intervention: Inpatient diabetes management and education with improved transition to outpatient care (IDMET)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 31
Study: 20689095

Group type: EXPERIMENTAL
Intervention: Pro-CHO (3.6 kcal/kg, 0.36 g protein/kg)
Number of subjects: 18
Study: 18573825

Group type: EXPERIMENTAL
Intervention: Interferon beta therapy
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (age- and sex-matched volunteers)
Number of subjects: 43
Study: 15818079

Group type: EXPERIMENTAL
Intervention: Physician's assessments of pain severity
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Physician's assessments of volume asymmetry
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Physician's assessments of temperature asymmetry
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Monitoring changes in symptoms between assessments
Number of subjects: 66
Study: 12809076

Group type: EXPERIMENTAL
Intervention: Testosterone treatment (200 mg intramuscularly every 2 weeks)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 36
Study: 10589852

Group type: EXPERIMENTAL
Intervention: Incremental respiratory muscle training (RMT) with resistive inspiratory and expiratory loads for 6 months
Number of subjects: 21

Group type: COMPARATOR
Intervention: No load training (NT)
Number of subjects: 21
Study: 8758538

Group type: EXPERIMENTAL
Intervention: Alpha Interferon therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus natural alpha Interferon
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High dose dexamethasone‐alpha Interferon
Number of subjects: 0

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study: 1913091

Group type: EXPERIMENTAL
Intervention: Iliofemoral bypass
Number of subjects: 74

Group type: COMPARATOR
Intervention: Femorofemoral bypass
Number of subjects: 74
Study: 6837688

Group type: EXPERIMENTAL
Intervention: Timolol
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control
Number of subjects: 32
Study: 31654784

Group type: EXPERIMENTAL
Intervention: WBRT 30 Gy/10 fractions
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: WBRT 37.5 Gy/15 fractions
Number of subjects: 194
Study: 29980851

Group type: EXPERIMENTAL
Intervention: Whey protein concentrate (0.33 g·kg BM‐1)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Whey protein concentrate (0.33 g·kg BM‐1) with prior aerobic exercise
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (75 g oral glucose tolerance test)
Number of subjects: 8
Study: 26916611

Group type: EXPERIMENTAL
Intervention: EXCAP (home-based walking and resistance intervention)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: EXCAP
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Wii-Fit (technology-mediated walking and resistance intervention)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Usual-care
Number of subjects: 19
Study: 25255414

Group type: EXPERIMENTAL
Intervention: Real-time feedback to residents alone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Real-time feedback to residents plus attending physicians
Number of subjects: 0
Study: 22153087

Group type: EXPERIMENTAL
Intervention: Ultrasound scalpel
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard scalpel blades, scissors, ligations, and electrocautery
Number of subjects: 60
Study: 20443797

Group type: EXPERIMENTAL
Intervention: Conical neck design implant (C)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Straight shape implant (S)
Number of subjects: 12
Study: 18509655

Group type: EXPERIMENTAL
Intervention: FDG-PET
Number of subjects: 72
Study: 15947874

Group type: EXPERIMENTAL
Intervention: Intake of fruit (highest vs lowest quintile)
Number of subjects: 36976

Group type: EXPERIMENTAL
Intervention: Intake of vegetables (highest vs lowest quintile)
Number of subjects: 36976

Group type: EXPERIMENTAL
Intervention: Total fiber intake (highest vs lowest quintile)
Number of subjects: 36976

Group type: EXPERIMENTAL
Intervention: Legume fiber intake (highest vs lowest quintile)
Number of subjects: 36976
Study: 12352800

Group type: EXPERIMENTAL
Intervention: CRM(197) pneumococcal conjugate vaccine (PCV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Meningococcal type C CRM(197) conjugate vaccine
Number of subjects: 0
Study: 10023873

Group type: EXPERIMENTAL
Intervention: Amnioinfusion
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control
Number of subjects: 112
Study: 7754005

Group type: EXPERIMENTAL
Intervention: Transcatheter arterial embolization (TAE) with gelatin sponge (GS) containing anticancer agents (protocol 1)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Transcatheter arterial embolization (TAE) with GS and iodized oil mixed with anticancer agents (protocol 2)
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Transcatheter arterial embolization (TAE) with iodized oil with anticancer agents (protocol 3)
Number of subjects: 322

Group type: COMPARATOR
Intervention: Transcatheter arterial embolization (TAE) with GS
Number of subjects: 322
Study: 2186321

Group type: EXPERIMENTAL
Intervention: CHOEP (cyclophosphamide 750 mg/m2 i.v. day 1, doxorubicin 50 mg/m2 i.v. day 1, vincristine 2 mg i.v. day 1, etoposide 100 mg/m2 i.v. days 3-5, prednisolone 100 mg p.o. days 1-5)
Number of subjects: 105

Group type: COMPARATOR
Intervention: hCHOP alternating with IVEP (cyclophosphamide 1,200 mg/m2 i.v. day 1, doxorubicin 40 mg/m2 i.v. days 1 + 2, vincristine 2 mg i.v. day 1, prednisolone 100 mg p.o. days 1-5)
Number of subjects: 105
Study: 6271848

Group type: EXPERIMENTAL
Intervention: delta‐9‐tetrahydrocannabinol
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: cannabidiol
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: cannabinol
Number of subjects: 27

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 27

Group type: COMPARATOR
Intervention: comparison group (nondrug users)
Number of subjects: 27
Study: 31916847

Group type: EXPERIMENTAL
Intervention: Self-efficacy
Number of subjects: 196

Group type: COMPARATOR
Intervention: Depression
Number of subjects: 196

Group type: COMPARATOR
Intervention: Anxiety
Number of subjects: 196
Study: 31153358

Group type: EXPERIMENTAL
Intervention: Scalp nerve block (SNB) with 15 mL of 0.75% ropivacaine
Number of subjects: 57

Group type: COMPARATOR
Intervention: Local anesthetic infiltration (LA) with 15 mL of 0.75% ropivacaine
Number of subjects: 57

Group type: COMPARATOR
Intervention: Routine intravenous analgesia (Control group)
Number of subjects: 57
Study: 28636855

Group type: EXPERIMENTAL
Intervention: RIV4 (45 μg of recombinant hemagglutinin [HA] per strain, 180 μg of protein per dose)
Number of subjects: 9003

Group type: COMPARATOR
Intervention: IIV4 (15 μg of HA per strain, 60 μg of protein per dose)
Number of subjects: 9003

Group type: EXPERIMENTAL
Intervention: RIV4
Number of subjects: 9003
Study: 25583168

Group type: EXPERIMENTAL
Intervention: elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/c/FTC/TDF)
Number of subjects: 200

Group type: COMPARATOR
Intervention: efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF)
Number of subjects: 200
Study: 24163991

Group type: EXPERIMENTAL
Intervention: Automatic positive airway pressure (APAP) titration
Number of subjects: 50

Group type: COMPARATOR
Intervention: Polysomnography manual titration
Number of subjects: 50
Study: 21324544

Group type: EXPERIMENTAL
Intervention: DLCST participants
Number of subjects: 3999

Group type: COMPARATOR
Intervention: Comparable population sample
Number of subjects: 3999
Study: 19752576

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 17683212

Group type: EXPERIMENTAL
Intervention: Rumination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Distraction
Number of subjects: 0
Study: 15526811

Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 69

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 69
Study: 11533270

Group type: EXPERIMENTAL
Intervention: (n‐3) PUFA
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: UDCA
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 35
Study: 9762784

Group type: EXPERIMENTAL
Intervention: Theophylline (10(-3) M)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Theophylline (10(-4) M)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isoproterenol
Number of subjects: 0
Study: 8156653

Group type: EXPERIMENTAL
Intervention: Metoclopramide 20 mg (0.2-0.3 mg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prochlorperazine 12.5 mg (0.1-0.2 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3131791

Group type: EXPERIMENTAL
Intervention: Alcohol (0.695 g/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31690107

Group type: EXPERIMENTAL
Intervention: 3 months of directly observed once-weekly rifapentine plus isoniazid
Number of subjects: 7452

Group type: COMPARATOR
Intervention: 9 months of self-administered daily isoniazid
Number of subjects: 7452
Study: 29769112

Group type: EXPERIMENTAL
Intervention: β-blockers
Number of subjects: 523
Study: 28098052

Group type: EXPERIMENTAL
Intervention: Dietary counselling on breast-feeding and complementary feeding during the 1st year of life (n=200)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Control group (n=300)
Number of subjects: 500
Study: 26433466

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy for Insomnia (CBT-I)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Relaxation Training (RT)
Number of subjects: 64
Study: 23231878

Group type: EXPERIMENTAL
Intervention: Culturally adapted cognitive behavioural therapy for psychosis (CaCBTp)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 35
Study: 21209123

Group type: EXPERIMENTAL
Intervention: ADA160/80 (160 mg at week 0, 80 mg at week 2, 40 mg at weeks 4 and 6)
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: ADA80/40 (80 mg at week 0, 40 mg at weeks 2, 4 and 6)
Number of subjects: 390

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 390
Study: 18282804

Group type: EXPERIMENTAL
Intervention: Shared-care model involving paediatric oncologists and family doctors
Number of subjects: 133